According to the research report titled ‘Global Allergy Immunotherapy Market Size study, by Treatment (Subcutaneous Therapy (SCIT), Sublingual Therapy (SLIT)), Allergy (Allergic rhinitis, Allergic conjunctivitis, Allergic asthma, Stinging insect venom, Others), Distribution Channel (Hospitals, E-commerce, Pharmacy) and Regional Forecasts 2020-2027’, available with Market Study Report, global allergy immunotherapy market was remunerated at USD 2.9 billion in 2019 and is projected to amass USD 6.6 billion by the year 2027, registering 10.85% CAGR over the next seven years.
 

Growing prevalence of allergic diseases, in tandem with non-profit organizations and governments increasing spending on clinical research & development are the key factors stimulating global allergy immunotherapy market growth.
 

According to the European Academy of Allergy and Clinical Immunology (EAACI), over 150 million people in Europe suffer from chronic food allergies, accounting for 20% of the nation’s population. The most common allergies are allergic rhinitis and asthma, which affect 100 million and 70 million people, respectively.
 

Request sample copy of this Report: https://www.marketstudyreport.com/request-a-sample/3029645/
 

For those unversed, allergy immunotherapy is a procedure for avoiding allergic reactions to dust, grass pollen, food, and bee venom among other things. It helps people with allergies including asthma, rhinitis, and conjunctivitis control their symptoms. 
 

Immunotherapy for allergies includes regular doses that are typically increased as the patient develops resistance. With a gradual increase in dosage, the patient's immune system becomes less vulnerable due to enhanced production of blocking antibodies that combat the foreign compounds causing allergies.
 

Product launches, mergers and acquisitions, alliances and agreements, investment, financing, and other tactics have been adopted by key players in the global allergy immunotherapy market to gain a competitive edge. Citing an instance, DBV Technologies SA signed a contract with Stallergenes S.A. in October 2017, for research & development in the field for averting birch allergy.
 

On the downside, hefty procedure costs and lack of skilled practitioners are anticipated to restrain worldwide allergy immunotherapy industry expansion over the forecast period. 
 

Considering the regional terrain, North America currently holds a major portion of global allergy immunotherapy market share, creditable to increasing clinical research & development spending by governments and non-profit organizations, along with rising cognizance regarding allergy care.
 

On the other hand, Asia Pacific industry is slated to grow substantially through 2027, attributable to pervasiveness of allergic diseases.
 

Leading organizations in global allergy immunotherapy market sphere are DBV Technologies SA, Circassia, Aimmune Therapeutics Inc., Anergis SA, Biomay AG, HAL Allergy B.V., Merck KGaA, Allergy Therapeutics plc, ALK-Abelló A/S, and Stallergenes Greer Ltd.